Drugs / Anti-CD19 UCAR-NK cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05654038 | Dec 2022 → Dec 2023 | B-cell acute lymphoblastic leukemia | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Unknown | No outcome recorded |
| Phase 1/2 | NCT05570188 | Oct 2022 → Oct 2024 | B-cell neoplasm, lymphoid leukemia | Kunming Hope of Health Hospital | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD19 U-CAR-NK cells | “The intervention in the trial is anti-CD19 U-CAR-NK cells, which belong to chimeric antigen receptor modified NK cells.” NCT05570188 ↗ |
| Known as | UCAR-NK | “anti-CD19 universal CAR-NK(UCAR-NK) cells therapy” NCT05654038 ↗ |
| Modality | Cell therapy | “The intervention in the trial is anti-CD19 U-CAR-NK cells, which belong to chimeric antigen receptor modified NK cells.” NCT05570188 ↗ |
| Route | Intravenous | “receive intravenous infusion of anti-CD19 UCAR-NK Cells” NCT05654038 ↗ |
| Target | CD19 | “anti-CD19 UCAR-NK cells” NCT05570188 ↗ |